What reimbursement challenges should diagnostic companies anticipate beyond 2026?

Payers are shifting toward outcomes-based reimbursement, tying molecular test payments to demonstrated clinical utility rather than analytical validity alone [13]. Companies lacking real-world evidence linking test results to treatment outcomes will face coverage denials. Read More

How does the IVDR affect non-European manufacturers exporting to the EU?

Non-EU manufacturers must appoint an authorized representative and meet identical clinical-evidence and post-market surveillance requirements as domestic firms [3]. Compliance timelines and costs often delay EU market entry by 12–18 months. Read More

Which sample types are gaining traction for decentralized molecular testing?

Saliva and nasal swabs are displacing venipuncture-dependent samples at point-of-care sites because they require no phlebotomy training [8]. Self-collection kits for HPV and STI testing are accelerating this shift. Read More

What role does bioinformatics outsourcing play in laboratory competitiveness?

Cloud-based variant interpretation services enable mid-size laboratories to offer NGS panels without in-house bioinformaticians [12]. This lowers fixed costs and compresses report turnaround to under 48 hours. Read More

How are pharmaceutical companies integrating molecular diagnostics into drug development?

Pharma firms increasingly co-develop companion diagnostics alongside therapeutic candidates, embedding biomarker-driven enrollment criteria into Phase II trials [6]. This reduces late-stage failure rates and speeds regulatory approval. Read More

What cybersecurity risks accompany cloud-connected molecular diagnostic platforms?

Connected sequencers and cloud-based LIMS systems introduce attack surfaces for ransomware and data exfiltration targeting protected health information [15]. FDA pre-market guidance now requires cybersecurity documentation for all networked diagnostic devices. Read More

How do multiplex panels change hospital antibiotic stewardship economics?

Syndromic panels identifying pathogens within 90 minutes enable targeted therapy initiation, reducing broad-spectrum antibiotic use by up to 30% and lowering average antimicrobial costs per patient admission [8]. Read More

Molecular Diagnostics Market (2026 - 2035)

ID: MRFR/HC/0665-CR

200 Pages

Nidhi Mandole

Last Updated: July 02, 2026

Molecular Diagnostics Market Research Report: Size, Share, Trend Analysis By Applications (Oncology, Infectious Diseases, Genetic Testing, Blood Screening, Other Applications), By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Microarrays, In Situ Hybridization, Other Technologies), By Product Type (Reagents, Instruments, Software, Consumables, Other Products), By End-user (Hospitals, Diagnostic Laboratories, Academic Institutions, Pharmaceutical Companies, Other End-users), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Molecular Diagnostics Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)9.58%

2025 Market SizeUSD 19.82 Billion

2035 Market SizeUSD 49.50 Billion

Key Players

Roche Diagnostics

Abbott Laboratories

Danaher

Hologic Inc.

bioMérieux

Qiagen N.V.

Trends

Payer Reimbursement Expansion for Genomic Tests
Sequencing Cost Deflation and Platform Miniaturization
Multiplex Syndromic Panel Adoption

Opportunities

Multi-Cancer Early Detection via Liquid Biopsy
Point-of-Care Molecular Testing in Retail Clinics
Emerging-Market Government Screening Programs

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 Broadening Payer Reimbursement for Genomic Profiling | |
  2. 3.1.2 Falling Sequencing Costs and Platform Miniaturization | |
  3. 3.1.3 Multiplex Syndromic Panel Adoption in Hospitals | |
  4. 3.1.4 Companion Diagnostic Regulatory Mandates | |
  5. 3.1.5 Government-Led Molecular Screening Programs in Asia | |
  6. 3.1.6 Liquid Biopsy Adoption for Multi-Cancer Early Detection | |
  7. 3.1.7 Pharmacogenomics Integration into Clinical Workflows |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 EU IVDR Compliance Costs Squeezing Smaller Manufacturers | |
  2. 3.2.2 Reimbursement Uncertainty for Novel LDTs | |
  3. 3.2.3 Skilled Workforce Shortages in Molecular Laboratories | |
  4. 3.2.4 Data Privacy Regulations Limiting Genomic Data Sharing | |
  5. 3.2.5 High Capital Expenditure for Sequencing Infrastructure |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 Multi-Cancer Early Detection via Liquid Biopsy | |
  2. 3.3.2 Point-of-Care Molecular Testing in Retail Clinics | |
  3. 3.3.3 Emerging-Market Government Screening Programs | |
  4. 3.3.4 Pharmacogenomics and Data Monetization | |
  5. 3.3.5 AI-Augmented Variant Interpretation Services |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Molecular Diagnostics Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD Billion) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Technology | |
  1. 5.1.1 Polymerase Chain Reaction (PCR) | |
  2. 5.1.2 Next-Generation Sequencing (NGS) | |
  3. 5.1.3 Fluorescence In Situ Hybridization (FISH) | |
  4. 5.1.4 Isothermal Amplification | |
  5. 5.1.5 Other Technologies |
2. 5.2 By Application | |
  1. 5.2.1 Infectious Disease | |
  2. 5.2.2 Oncology | |
  3. 5.2.3 Genetic Testing | |
  4. 5.2.4 Pharmacogenomics | |
  5. 5.2.5 Other Applications |
3. 5.3 By Product | |
  1. 5.3.1 Reagents & Kits | |
  2. 5.3.2 Instruments & Systems | |
  3. 5.3.3 Software & Services |
4. 5.4 By Sample Type | |
  1. 5.4.1 Blood, Serum & Plasma | |
  2. 5.4.2 Urine | |
  3. 5.4.3 Tissue | |
  4. 5.4.4 Other Sample Types |
5. 5.5 By End User | |
  1. 5.5.1 Diagnostic & Reference Laboratories | |
  2. 5.5.2 Hospitals | |
  3. 5.5.3 Academic & Research Institutions | |
  4. 5.5.4 Clinics & Ambulatory Care | |
  5. 5.5.5 Other End Users
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 United Kingdom | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of MEA
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2025) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 Roche Diagnostics | |
  2. 7.3.2 Abbott Laboratories | |
  3. 7.3.3 Danaher (Cepheid) | |
  4. 7.3.4 Hologic Inc. | |
  5. 7.3.5 bioMérieux | |
  6. 7.3.6 Qiagen N.V. | |
  7. 7.3.7 Becton Dickinson | |
  8. 7.3.8 Siemens Healthineers | |
  9. 7.3.9 Illumina Inc. | |
  10. 7.3.10 Thermo Fisher Scientific
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 AI-Driven Diagnostics and Algorithmic Interpretation |
2. 8.2 Decentralized and Point-of-Care Testing Expansion |
3. 8.3 Liquid Biopsy and Multi-Cancer Early Detection |
4. 8.4 Pharmacogenomics and Population Health Integration
9 Recent Developments & News
10 Frequently Asked Questions (FAQs)
11 Report Scope & Methodology |
1. 11.1 Study Period & Base Year |
2. 11.2 Data Sources & Citations |
3. 11.3 Abbreviations
12 LIST OF TABLES |
TABLE 1 Global Molecular Diagnostics Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Molecular Diagnostics Market — Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Market Driver Impact Analysis, 2026–2035 |
TABLE 4 Market Restraint Impact Analysis, 2026–2035 |
TABLE 5 Regional Market Share Summary, 2025 |
TABLE 6 North America Molecular Diagnostics Market, by Country, 2021–2035 |
TABLE 7 Europe Molecular Diagnostics Market, by Country, 2021–2035 |
TABLE 8 Asia-Pacific Molecular Diagnostics Market, by Country, 2021–2035 |
TABLE 9 South America Molecular Diagnostics Market, by Country, 2021–2035 |
TABLE 10 Middle East & Africa Molecular Diagnostics Market, by Country, 2021–2035 |
TABLE 11 Global Molecular Diagnostics Market, by Technology, 2021–2035 |
TABLE 12 Global Molecular Diagnostics Market, by Application, 2021–2035 |
TABLE 13 Global Molecular Diagnostics Market, by Product, 2021–2035 |
TABLE 14 Global Molecular Diagnostics Market, by Sample Type, 2021–2035 |
TABLE 15 Global Molecular Diagnostics Market, by End User, 2021–2035 |
TABLE 16 Competitive Benchmarking Matrix — Global Molecular Diagnostics Market, 2025 |
TABLE 17 Company Profiles — Key Players, Global Molecular Diagnostics Market |
TABLE 18 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 19 Report Scope & Methodology Summary |
TABLE 20 Detailed Sources and Citations
13 LIST OF FIGURES |
FIGURE 1 Global Molecular Diagnostics Market Dynamics — Drivers, Restraints, and Opportunities |
FIGURE 2 Industry Value Chain Analysis — Molecular Diagnostics Market |
FIGURE 3 Porter's Five Forces Analysis — Molecular Diagnostics Market |
FIGURE 4 Global Molecular Diagnostics Market Size Trend (USD Billion), 2021–2035 |
FIGURE 5 Molecular Diagnostics Market Share, by Technology, 2025 |
FIGURE 6 Molecular Diagnostics Market Share, by Application, 2025 |
FIGURE 7 Molecular Diagnostics Market Share, by Product, 2025 |
FIGURE 8 Molecular Diagnostics Market Share, by Sample Type, 2025 |
FIGURE 9 Molecular Diagnostics Market Share, by End User, 2025 |
FIGURE 10 Molecular Diagnostics Market Share, by Region, 2025 |
FIGURE 11 North America Molecular Diagnostics Market — Country Share, 2025 |
FIGURE 12 Europe Molecular Diagnostics Market — Country Share, 2025 |
FIGURE 13 Asia-Pacific Molecular Diagnostics Market — Country Share, 2025 |
FIGURE 14 Competitive Landscape — Market Concentration and Top-5 Share, 2025

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
Technology	PCR, NGS, FISH, Isothermal Amplification, Other	Polymerase Chain Reaction (PCR)	Next-Generation Sequencing (NGS)
Application	Infectious Disease, Oncology, Genetic Testing, Pharmacogenomics, Other	Infectious Disease	Oncology
Product	Reagents & Kits, Instruments & Systems, Software & Services	Reagents & Kits	Instruments & Systems
Sample Type	Blood/Serum/Plasma, Urine, Tissue, Other	Blood, Serum & Plasma	Urine
End User	Diagnostic & Reference Labs, Hospitals, Academic & Research, Clinics & Ambulatory, Other	Diagnostic & Reference Laboratories	Clinics & Ambulatory Care
Geography	North America, Europe, Asia-Pacific, South America, MEA	North America	Asia-Pacific

Market Segmentation Overview

By Technology

Sub-Segment	Key Trend
Polymerase Chain Reaction (PCR)	Multiplex syndromic panel proliferation in hospital EDs; digital PCR for MRD monitoring
Next-Generation Sequencing (NGS)	Rapid cost deflation below USD 200/genome; oncology panel expansion
Fluorescence In Situ Hybridization (FISH)	Continued use in hematologic malignancy cytogenetics
Isothermal Amplification	Point-of-care deployment in CLIA-waived settings; LAMP-based platforms
Other Technologies	Microarray resurgence for pharmacogenomics; MALDI-TOF mass spectrometry

PCR dominates with an established installed base and broad reimbursement, while NGS is the growth engine driven by oncology profiling, liquid biopsy applications, and population sequencing programs.

By Application

Sub-Segment	Key Trend
Infectious Disease	Sustained demand for respiratory, STI, and blood-safety syndromic panels
Oncology	Companion diagnostic mandates; liquid biopsy and MCED test launches
Genetic Testing	Expanded carrier screening; non-invasive prenatal testing adoption
Pharmacogenomics	EHR integration of pre-emptive drug-metabolism panels
Other Applications	Transplant rejection monitoring; forensic DNA identification

Infectious disease holds the largest share due to high test volumes, while oncology is the fastest-growing application driven by regulatory requirements linking drug access to biomarker testing.

By Product

Sub-Segment	Key Trend
Reagents & Kits	Razor-and-blade consumable model; recurring revenue streams
Instruments & Systems	Platform refresh cycles; compact POC molecular analyzers
Software & Services	Cloud bioinformatics; AI-assisted variant interpretation

Reagents and kits generate the majority of revenue, while instruments and systems grow fastest as laboratories upgrade to next-generation platforms and point-of-care devices.

By Sample Type

Sub-Segment	Key Trend
Blood, Serum & Plasma	Liquid biopsy; blood-safety NAT screening; cfDNA extraction
Urine	STI molecular testing; BK virus monitoring in transplant
Tissue	FFPE tumor profiling; surgical margin assessment
Other Sample Types	Saliva self-collection; CSF meningitis panels

Blood-based samples dominate due to liquid biopsy growth and blood-bank nucleic acid testing, while urine-based testing is expanding rapidly through at-home STI collection kits.

By End User

Sub-Segment	Key Trend
Diagnostic & Reference Laboratories	Centralization of complex sequencing workflows
Hospitals	In-house syndromic panels; rapid molecular POC integration
Academic & Research Institutions	Translational genomics; clinical trial biomarker services
Clinics & Ambulatory Care	Retail-clinic CLIA-waived molecular testing rollouts
Other End Users	Public-health laboratories; blood banks

Reference laboratories lead in market share for high-complexity testing, while hospitals and ambulatory clinics represent the fastest-growing end-user segments as molecular testing decentralizes.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”